Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

NCT06803693 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

152

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Polatuzumab vedotin
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Prednisone
DRUG: Zanubrutinib
DRUG: Lenalidomide
DRUG: Decitabine

Sponsor

Ruijin Hospital